panflu Stats

[Mixin]

Biotech drug developer Vical Inc. said Friday its pandemic bird flu vaccine candidate Vaxfectin was safe and effective in an early clinical trial.

Vaxfectin was tested on about 100 patients in the proof-of-concept study. Vical said the vaccine caused antibody formation and T-cell responses against the H5N1 strain of the virus. When the vaccine was given in high doses, Vical said there was evidence of antibody responses in 67 percent of subjects.

The San Diego-based company added that the responses persisted six months, through the end of the study, which suggests the vaccine could provide long-lasting protection. Vical said Vaxfectin may also provide protection against other strains of the influenza virus.

The results were presented at a World Health Organization conference in Geneva.
http://www.businessweek.com/ap/financialnews/D96AMM480.htm
_________________
https://twitter.com/mixin1771